Metastasis-free survival as a surrogate endpoint in prostate cancer clinical trials

As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …

IL-35 levels in the diagnosis and prognosis of prostate cancer

A new paper by a group of Chinese researchers has suggested that levels of a biochemical called interleukin-35 (IL-35) in blood plasma may offer evidence of the presence of prostate cancer and do so significantly better than PSA levels (particularly for men with PSA levels of between 4 and 10 ng/ml). … READ MORE …

The proposed, Finnish, ProScreen trial

A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment. … READ MORE …

The TOAD trial: follow-up data on quality of life

Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …

“Discussing overdiagnosis is good science”

The term “over-diagnosis” didn’t exist 15 years ago in the management of prostate cancer. (Well, actually it did, but it would very rarely — if ever — have come to the notice of any patient or even of the average urologist or primary care physician.) … READ MORE …

Height IS a risk factor for higher-risk prostate cancer

A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …

An update on “screening” for prostate cancer: four perspectives

To quote the abstract of the paper discussed below, the use of the PSA test to screen for risk of prostate cancer “in men at normal risk of prostate cancer is one of the most contested issues in cancer screening.” No! Really? … READ MORE …